Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

White House economic adviser Peter Navarro said on Tuesday that recommendations from health experts that convalescent plasma undergo a randomized trial as a COVID-19 treatment before receiving an emergency authorization are a "crazy talking point."

Why it matters: Top federal health officials urged the FDA last week to hold off on issuing an emergency use authorization for the safe, but unproven treatment, but the agency went ahead with it on Sunday amid pressure from Navarro and Trump.

  • The National Institutes of Health's Francis Collins, Anthony Fauci and H. Clifford Lane were among the scientists who sought to intervene to stop the FDA from immediately authorizing plasma due to the absence of strong data about its effectiveness.
  • “The three of us are pretty aligned on the importance of robust data through randomized control trials, and that a pandemic does not change that,” Lane told the New York Times.

Yes, but: The FDA said in a statement that the authorization "is not intended to replace randomized clinical trials and facilitating the enrollment of patients into any of the ongoing randomized clinical trials is critically important for the definitive demonstration of safety and efficacy of COVID-19 convalescent plasma."

The big picture: The FDA authorization came one day after President Trump accused the administration of slow-walking the development of vaccines and therapeutics for political purposes. Earlier in the week, Navarro accused health officials of being part of the "deep state" and urged them to get on "Trump time."

What they're saying: "On the issue of not being able to do randomized trials, what is the calculus here? Are we going to wait to use something that can save thousands of lives just so we can have a study that tells us what we already know?" Navarro told MSNBC.

  • "The odds of this being able to hurt you are close to zero, so it's safe. The odds of it being able to help you are close to 100%," Navarro claimed.
  • Reality check: The odds of plasma being able to help COVID-19 patients are not "close to 100%."

The other side: Speaker Nancy Pelosi told MSNBC after Navarro's appearance that the Trump administration is "politicizing science." She warned of the need to watch out for the politicization of the vaccine process because the Trump administration has "already indicated that they will overstate the safety and the efficacy of a drug."

Go deeper: FDA commissioner says criticism of his plasma comments was justified

Go deeper

WH coronavirus task force: States must "flatten the curve" to sustain health system

A walk-up Covid-19 testing site in San Fernando, California, on Nov. 24, ahead of the Thanksgiving holiday.

The White House coronavirus task force warned states "the COVID risk to all Americans is at a historic high" and to brace for another surge following Thanksgiving, per a report that emerged Wednesday.

Driving the news: "If you are under 40, you need to assume you became infected during the Thanksgiving period if you gathered beyond your immediate household," said the report, dated Nov. 29, first published by the Center for Public Integrity.

Dec 3, 2020 - Health

U.S. exceeds 100,000 COVID-related hospitalizations for the first time

People wait outside the Emergency room of the Garfield Medical Center in Monterey Park, California on Dec 1. Photo: Frederic J. Brown/Getty Images

More than 100,200 Americans were hospitalized as of Wednesday due to the coronavirus for the first time since the outbreak began in early 2020, per the COVID Tracking Project.

The big picture: The milestone comes as health officials anticipated cases to surge due to holiday travel and gatherings. The impact of the holiday remains notable, as many states across the country are only reporting partial data.

Pelosi, Schumer call on McConnell to adopt bipartisan $900B stimulus framework

House Speaker Nancy Pelosi on Nov. 20. Photo: Drew Angerer/Getty Images

House Speaker Nancy Pelosi (D-Calif.) and Senate Minority Leader Chuck Schumer (D-N.Y.) on Wednesday urged Senate Majority Leader Mitch McConnell (R-Ky.) to use a $908 billion bipartisan coronavirus relief framework as a basis for jumpstarting negotiations.

Why it matters: The framework, introduced by a group of bipartisan lawmakers on Tuesday, calls for significantly less funding than Pelosi had previously demanded — a sign that Democrats are ready to further compromise as millions of Americans endure economic hardship.